Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | ABL2 | P42684 | 1/20 | 0.52 |
| ▸ | FBP1 | P09467 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14051691 | 0.81 | HDAC1 (0.39) | ALDH1A1MAPTKMT2AHDAC1SMN1; SMN2 | |
| SCHEMBL2606218 | 0.78 | HDAC1 (0.39) | ALDH1A1MAPTLMNAKMT2ACYP3A4 | |
| SCHEMBL28013104 | 0.75 | FBP1 (0.49) | EGFRABL1ABL2FBP1CYP3A4 | |
| SCHEMBL11436689 | 0.74 | HDAC1 (0.39) | ALDH1A1MAPTLMNAKMT2ACYP3A4 | |
| SCHEMBL4256803 | 0.73 | CYP3A4 (0.59) | FBP1ALDH1A1MAPTLMNAKMT2A | |
| SCHEMBL4256807 | 0.73 | CYP3A4 (0.59) | FBP1ALDH1A1MAPTLMNAKMT2A | |
| SCHEMBL4588444 | 0.72 | MAPT (0.42) | ALDH1A1MAPTKMT2ACYP3A4NAMPT | |
| SCHEMBL1160196 | 0.72 | CYP2A6 (0.47) | ALDH1A1MAPTCYP3A4NAMPTXDH | |
| SCHEMBL29505633 | 0.72 | CYP2A6 (0.47) | ALDH1A1MAPTCYP3A4NAMPTXDH | |
| Acetic Acid SCHEMBL28050837 | 0.71 | CYP3A4 (0.65) | ALDH1A1MAPTLMNAKMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200237717-A1 | Treatment of Staphylococcal and Enterococcal Infections Using Substituted Nitrostyrene Compounds | Opal Biosciences Limited (AU) | 2020-07-30 | — | — | US | disclosed |
| US-9867802-B2 | Method of treating Scedosporium spp. infection | BIODIEM LIMITED (AU) | 2018-01-16 | — | — | US | disclosed |
| US-9867802-B2 | Method of treating Scedosporium spp. infection | BIODIEM LIMITED (AU) | 2018-01-16 | — | — | US | disclosed |
| US-20150258059-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | BIODIEM LTD (AU) | 2015-09-17 | — | — | US | disclosed |
| US-20150258059-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | BIODIEM LTD (AU) | 2015-09-17 | — | — | US | disclosed |
| US-9045452-B2 | Antimicrobial and radioprotective compounds | BIODIEM LTD. (AU) | 2015-06-02 | — | — | US | disclosed |
| US-9045452-B2 | Antimicrobial and radioprotective compounds | BIODIEM LTD. (AU) | 2015-06-02 | — | — | US | disclosed |
| US-20150126436-A1 | METHOD OF TREATING SCEDOSPORIUM SPP. INFECTION | BIODIEM LIMITED (AU) | 2015-05-07 | — | — | US | disclosed |
| US-20150126436-A1 | METHOD OF TREATING SCEDOSPORIUM SPP. INFECTION | BIODIEM LIMITED (AU) | 2015-05-07 | — | — | US | disclosed |
| US-20140080876-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | BIODIEM LTD (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20120225935-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | BIODIEM LTD. (AU) | 2012-09-06 | — | — | US | disclosed |
| US-20120225935-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | BIODIEM LTD. (AU) | 2012-09-06 | — | — | US | disclosed |
| EP-2471531-A2 | Nitro-styrene derivatives having antimicrobial activity | Biodiem Ltd. (AU) | 2012-07-04 | — | — | EP | disclosed |
| EP-2468275-A1 | Nitrostyrenederivatives with antimicrobial action | Biodiem Ltd. (AU) | 2012-06-27 | — | — | EP | disclosed |
| EP-2468276-A1 | Nitrostyrene derivatives having antimicrobial action | Biodiem Ltd. (AU) | 2012-06-27 | — | — | EP | disclosed |
| US-8158664-B2 | Antimicrobial and radioprotective compounds | BIODIEM LTD. (AU) | 2012-04-17 | — | — | US | disclosed |
| US-20100292317-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | BIODIEM LTD. (AU) | 2010-11-18 | — | — | US | disclosed |
| US-7825145-B2 | Antimicrobial and radioprotective compounds | BIODIEM LTD (AU) | 2010-11-02 | — | — | US | disclosed |
| US-20090012137-A1 | administering microbiocides such as 3,4-methylenedioxy- beta -nitrostyrene, for the treatment of urogenital disorders caused by Candida, Neisseria, Chlamydia or Trichomonas; side effect reduction of radiotherapy | BIODIEM LTD. (AU) | 2009-01-08 | — | — | US | disclosed |
| WO-2008061308-A1 | PROTEIN TYROSINE PHOSPHATASE MODULATORS | BIODIEM LTD (AU) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126436-A1 | METHOD OF TREATING SCEDOSPORIUM SPP. INFECTION | ERG28, CYP51A1, SORD | EGFR 4723/4885ABL1 1427/4885ABL2 970/4885 |
| US-20200237717-A1 | Treatment of Staphylococcal and Enterococcal Infections Using Substituted Nitrostyrene Compounds | APP, AHR, ESD | EGFR 1363/4885ABL1 3616/4885ABL2 1305/4885 |
| US-20140080876-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | RAD51, BRCA1, XPA | EGFR 1313/4885ABL1 2850/4885ABL2 2441/4885 |
| US-20150258059-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | RAD51, BRCA1, XPA | EGFR 1313/4885ABL1 2850/4885ABL2 2441/4885 |
| US-20100292317-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | RAD51, BRCA1, XPA | EGFR 1313/4885ABL1 2850/4885ABL2 2441/4885 |
| US-20090012137-A1 | administering microbiocides such as 3,4-methylenedioxy- beta -nitrostyrene, for the treatment of urogenital disorders caused by Candida, Neisseria, Chlamydia or Trichomonas; side effect reduction of radiotherapy | TUBB1, UGT1A1, CYP1A1 | EGFR 2912/4885ABL1 3274/4885ABL2 3359/4885 |
| US-20120225935-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | QSOX1, RAD50, RAD51 | EGFR 1985/4885ABL1 2952/4885ABL2 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.